German biopharmaceutical firm Sartorius on Thursday reported a decline in its nine-month underlying net profit, which fell to €208 million ($226 million) from €274 million in the previous year. The company’s underlying earnings per ordinary share also dropped to €3.01, down from €4.00 last year. In the first nine months of the fiscal year, Sartorius reported a sales revenue decline of 2.0% in constant currencies and 2.8% in reported terms compared to the previous year, bringing the total to €2.47 billion. However, the company saw an increase in order intake, which rose significantly by 6.6% in…